Filing Flows › Crispr Therapeutics AG (CRSP) › Q2 2026 › vs Q2 2025
Crispr Therapeutics AG (CRSP) Q2 2026 vs Q2 2025 (year over year)
Crispr Therapeutics AG's revenue rose $9.3M (11×) from $892K in Q2 2025 to $10.2M in Q2 2026. The biggest changes: Collaboration Revenue +$10.0M (—); Grant −$711K (-80%).
Crispr Therapeutics AG, Q2 2026: revenue $10.2M (11× year over year), net loss $91.2M, operating cash flow −$83.5M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Collaboration Revenue | $10.0M | $0 | $10.0M | — |
| Grant | $181K | $892K | −$711K | -80% |
| Revenue | $10.2M | $892K | $9.3M | 11× |
| Other income, net | $27.1M | $22.1M | $5.0M | +23% |
| Net loss | $91.2M | $209M | −$117M | -56% |
| Costs & expenses | $128M | $232M | −$103M | -45% |
| Operating costs | $127M | $230M | −$103M | -45% |
| Income tax | $960K | $1.3M | −$332K | -26% |
| Research & development | $67.2M | $69.9M | −$2.7M | -4% |
| General & admin | $17.6M | $18.9M | −$1.4M | -7% |
| Other operating costs | $42.7M | $141M | −$98.7M | -70% |
| Operating cash sources | $105M | $136M | −$31.0M | -23% |
| Depreciation & amortization | $4.3M | $4.6M | −$369K | -8% |
| Share-based compensation | $17.3M | $17.6M | −$291K | -2% |
| Cash used in operations | $83.5M | $114M | −$30.4M | -27% |
| Net loss absorbed | $91.2M | $209M | −$117M | -56% |
| Working capital & other | $13.9M | −$72.4M | $86.4M | — |
Questions
How much did Crispr Therapeutics AG's revenue grow year over year in Q2 2026?
Crispr Therapeutics AG's revenue rose $9.3M (11×) from $892K in Q2 2025 to $10.2M in Q2 2026.
What drove Crispr Therapeutics AG's revenue change in Q2 2026?
Collaboration Revenue +$10.0M (—); Grant −$711K (-80%).